GTC Biotherapeutics (fka GTCB)

[n4807g]

Last time I checked the BOD's primary responsibility is protecting and enhancing the value of the company for the shareholders benefit. You're right; the entire future of this company does ride on the pending decision on ATryn. I don't see this situation as a "success", but rater a "failure". It's hard to imagine the fate of a company whittled down to a panel decision on one drug.

The BOD and exec's seem to have managed to maneuver the company into a very precarious position. I don't consider that particularly impressive?

Let us hope the FDA gives swift approval, for the sake of all the long term shareholders.